Olema: 'Strong Buy' Maintained On OPERA-02 Trial Initiation & Additional Shots On Goal [Seeking Alpha]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Seeking Alpha
Company's palazestrant + KISQALI combination achieved a promising 15.5-month mPFS in heavily pretreated patients, addressing endocrine resistance in both ESR1-mutant and wild-type tumors. Key catalysts include OPERA-01 monotherapy data expected in 2H 2026 and OPERA-02 topline results in 2028, with potential NDA filing in 2027 for monotherapy if successful. Recent capital raises bolster OLMA's cash runway, but clinical and combination risks remain, particularly regarding efficacy translation and partner drug differentiation. Noko LTD/E+ via Getty Images The last time I spoke about Olema Pharmaceuticals OLMA ) it was with respect to a Seeking Alpha article entitled " Olema: Cash Infusion And Supply Agreement With Novartis Carries The Tide Forward More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm cur
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- 2 Top Stocks to Buy and Hold for the Long Term [Yahoo! Finance]Yahoo! Finance
- Nine Drugmakers Strike Deals With Trump, More Coming Next Year [Yahoo! Finance]Yahoo! Finance
- Novartis and US government reach agreement on lowering drug prices in the US [Yahoo! Finance]Yahoo! Finance
- Novartis' myasthenia gravis asset iptacopan granted FDA Orphan Drug status [Seeking Alpha]Seeking Alpha
- Corporate director convicted of insider trading [Investment Executive - News]Investment Executive - News
NVS
Earnings
- 10/28/25 - Miss
NVS
Sec Filings
- 11/25/25 - Form 6-K
- 11/20/25 - Form 6-K
- 11/5/25 - Form 6-K
- NVS's page on the SEC website